Related Experiment Videos
Effect of pulse loading with clomipramine on EEG sleep
D J Kupfer1, B G Pollock, J M Perel
1Dept. of Psychiatry, WPIC, Pittsburgh, PA 15213-2593, USA.
Psychiatry Research
|November 1, 1994
Summary
Investigating clomipramine (CMI) dosing for major depressive disorder, this study found pulse-loading CMI led to faster REM sleep rebound in responders. This suggests CMI
Area of Science:
- Pharmacology
- Neuroscience
- Psychiatry
Background:
- Major depressive disorder (MDD) treatment often involves optimizing antidepressant dosing strategies.
- Clomipramine (CMI), a tricyclic antidepressant, affects sleep architecture, particularly rapid eye movement (REM) sleep.
- Understanding early response indicators can guide treatment adjustments for MDD.
Purpose of the Study:
- To compare two initial dosing regimens of clomipramine (CMI) for major depressive disorder.
- To identify early indicators of treatment response related to sleep parameters.
- To evaluate dose strategies for clomipramine in an inpatient setting.
Main Methods:
- Thirty-two inpatients with MDD were randomized into a double-blind study.
- One group received pulse-loading clomipramine (150-200 mg on consecutive evenings, then placebo).
- The other group received traditional gradual clomipramine titration (starting at 50 mg, increasing to 200 mg).
Main Results:
- Both dosing regimens significantly suppressed REM sleep.
- The pulse-loading group showed a faster and more robust REM sleep rebound in responders compared to non-responders.
- A correlation was observed between falling desmethylclomipramine metabolite levels and REM sleep activity during rebound.
Conclusions:
- Pulse-loading clomipramine may serve as an effective initial dosing strategy for MDD.
- REM sleep rebound dynamics can be an early indicator of clomipramine response.
- Metabolite levels of clomipramine correlate with REM sleep changes, offering potential insights into treatment mechanisms.